Aridis Pharmaceuticals, Inc. has appointed to its senior management team, Wolfgang Dummer, M.D., Ph.D., as Chief Medical Officer, and Mitchell H. Rosner as Vice President of Quality....
Aridis Pharmaceuticals, Inc. has appointed to its senior management team, Wolfgang Dummer, M.D., Ph.D., as Chief Medical Officer, and Mitchell H. Rosner as Vice President of Quality....
Aridis Pharmaceuticals, Inc. today announced that it has created a joint venture with Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (Hepalink), one of China’s leading pharmaceutical companies, to develop and gain regulatory approval for Aridis’ fully human monoclonal antibody (mAb) therapies for the greater China market....
Aridis Pharmaceuticals, Inc. today announced the appointment of Alan H. Cohen, MD, FAAP, FCCP, FAAAAI, FACAAI, as Senior Vice President of Clinical & Medical Affairs. Dr. Cohen has served as a Medical Consultant and Advisor to Aridis for more than 10 years, leveraging his extensive...
Aridis Pharmaceuticals, Inc. today announced that it is now actively enrolling patients in a global pivotal study of Aerucin®, the Company’s broadly reactive monoclonal antibody being developed to treat acute pneumonia caused by Gram-negative bacteria Pseudomonas aeruginosa. The randomized, double-blinded, placebo-controlled trial is ongoing in...
Aridis Pharmaceuticals, Inc. today presented top-line results of its Phase 2a trial of Salvecin™ (AR-301), its human monoclonal antibody used as an adjunct therapy for severe pneumonia caused by Staphylococcus aureus, at the ASM Microbe congress held, June 1 – 5, 2017, in New Orleans....
Aridis Pharmaceuticals, Inc. announced today it has secured a therapeutics development award from Cystic Fibrosis Foundation Therapeutics (CFFT), the drug discovery and development affiliate of the Cystic Fibrosis Foundation, the world’s leader in the search for a cure for cystic fibrosis (CF)....
Aridis Pharmaceuticals, Inc. today announced positive clinical results from its Phase 1/2a study of AR-301, its fully human monoclonal antibody against Staphylococcus aureus alpha-toxin being evaluated as an adjunctive therapy in combination with standard of care antibiotics for hospital-acquired pneumonia and ventilator-associated pneumonia (“HAP” and...
Aridis Pharmaceuticals, Inc. announced today that CEO Vu Truong, Ph.D., will participate on a panel at the 2016 Anti-Infectives Rx Conference, held September 21, 2016, and hosted by Boston Biotech Conferences....
Aridis Pharmaceuticals, Inc. announced today the addition of three highly recognized experts, Bruno Francois, M.D., Jean Chastre, M.D., and Marin Kollef, M.D., F.A.C.P., F.C.C.P., to the company’s Clinical Advisory Board. ...